Other mRNAs with partial complementarity

Other mRNAs with partial complementarity refers to a broad category of messenger RNA (mRNA) molecules that are unintentionally targeted by oligonucleotide-based therapeutics, such as small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs). While these drugs are designed to bind with high specificity to a single target mRNA, they can also hybridize with other transcripts that share partial sequence homology, particularly within the 6-8 nucleotide seed region (Jackson et al., 2003, Nature Biotechnology). This unintended interaction can lead to the degradation or translational inhibition of these non-target mRNAs, potentially causing adverse effects or off-target toxicity (Birmingham et al., 2006, Nature Methods). In drug development, minimizing these interactions is crucial for ensuring the safety and specificity of RNA-targeted therapies (Fedorov et al., 2006, RNA). This phenomenon is often mediated by the RNA-induced silencing complex (RISC) in the case of siRNAs or by RNase H in the case of certain ASOs (Kurreck, 2003, European Journal of Biochemistry). The resulting unintended gene knockdown can lead to a variety of safety concerns, including hepatotoxicity or altered cellular metabolism, depending on the function of the affected mRNA (Burchard et al., 2009, Nucleic Acids Research). Consequently, this term is frequently used in bioinformatics and toxicology to describe the pool of transcripts at risk for unintended silencing during the screening of lead compounds.

Other names

Off-target mRNAsNon-target transcriptsSeed-matched transcriptsPartially complementary mRNA sequencesOff-target gene transcripts

Unintended hybridization of therapeutic oligonucleotides to non-target mRNA transcripts through partial base-pairing, leading to RISC-mediated cleavage or RNase H-dependent degradation.